Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
192
resultados
Última actualización
16/06/2025 [06:52:00]
Resultados 125 a 150 de 192
Resumen de: US2025177514A1
The present disclosure provides isolated immunogenic polypeptides comprising variant coronavirus spike proteins that are variants of a native coronavirus spike protein or fragment thereof, the variant coronavirus spike proteins having one or more modifications compared to the native coronavirus spike protein that: increase adoption by a receptor binding domain (RBD) of the variant coronavirus spike protein of an up conformation; and/or decrease adoption by a RBD of the variant coronavirus spike protein of a down conformation; and/or increase expression of the variant coronavirus spike protein compared to the native coronavirus spike protein; and/or increase adoption of a prefusion conformation; and/or decrease shedding of a S1 subunit of the variant coronavirus spike protein; and/or improve localization of the variant coronavirus spike protein to a host cell membrane. The present disclosure also provides compositions comprising the isolated immunogenic polypeptides and methods of making and using such compositions.
Resumen de: US2025177512A1
The present specification relates to vaccines comprising an mRNA polynucleotide encoding an antigen from an infectious microorganism; and an amphipathic cell penetrating RALA peptide.
Resumen de: US2025177503A1
The present invention relates to compositions comprising nanoparticles associated with or without one or more tolerogenic antigens, and compositions comprising an immunomodulatory agent (e.g., interleukin-2 (IL-2) or an IL-2 variant or an IL-2/IC)), and related methods involving co-administration of such compositions for purposes of inducing amplification of regulatory T cells (Tregs) (e.g., antigen-specific regulatory Tregs). The present invention further provides methods of treating autoimmune disorders through administering to a subject a composition comprising nanoparticles associated with or without one or more tolerogenic antigens associated with the autoimmune disorder prior to administering to the subject a composition comprising an immunomodulatory agent.
Resumen de: US2025177560A1
Functionalized nanoparticles for inhibiting or preventing pathogen infections (e.g., viral or bacterial infections, such as coronavirus infections) are described. The nanoparticles comprise a biodegradable polymer core and a lipid coating layer that is functionalized with a pathogen-binding receptor (e.g., an angiotensin-converting enzyme 2 (ACE2) receptor protein) and/or a pathogen-binding antibody or an antigen-binding fragment thereof (e.g., a virus-binding antibody or an antigen-binding fragment thereof). The nanoparticles are further functionalized by a phagocyte-specific ligand, e.g., a phosphatidylserine-containing lipid included in the lipid coating layer, to promote clearance of nanoparticle-bound pathogen. Methods of using the nanoparticles to treat or prevent pathogen infections (e.g., coronavirus infections) are also described.
Resumen de: US2025177556A1
Disclosed herein are methods and compositions related to delivery of pharmaceutical agents by lipid nanoparticles (LNPs) to a cell of a target organ (e.g., an eye, an ear) of a subject.
Resumen de: US2025177303A1
In various embodiments, drug delivery vehicles are provided for co-delivery of a chemotherapeutic agent and a TLR7/8 agonist and/or a lipoxin to a cancer. In certain embodiments the vehicles comprise a silicasome comprising: a porous nanoparticle encapsulated in a lipid bilayer, where the lipid bilayer contains a lipoxin and/or a lipid compatible TLR7/8 agonist disposed in the lipid bilayer, and the chemotherapeutic agent is contained in pores comprising the porous nanoparticle and the chemotherapeutic agent comprises a chemotherapeutic agent that induces immunogenic cell death (ICD); or a liposome comprising a lipid bilayer where the lipid bilayer contains a lipoxin and/or a lipid compatible a TLR7/8 agonist disposed in the lipid bilayer; and the chemotherapeutic agent is inside the liposome and the chemotherapeutic agent comprises a chemotherapeutic agent that induces immunogenic cell death (ICD).
Resumen de: US2025177532A1
The present invention relates to: a temperature-sensitive hydrogel for cancer treatment; a photothermal composition comprising the hydrogel as an active ingredient; and a preparation method for the temperature-sensitive hydrogel for cancer treatment. The temperature-sensitive hydrogel of the present invention includes gold nanostars as active ingredients, and thus can generate heat by light irradiation, thereby exhibiting a photothermal therapy effect. In addition, the hydrogel temperature increases so that the release of nitric oxide (NO) from S-nitrosocysteine can be induced. In addition, the temperature-sensitive hydrogel of the present invention includes S-nitrosocysteine as an active ingredient so that, upon a temperature rise due to a photothermal reaction, the penetration of drugs into a tumor site can be improved by the release of NO, and at the same time, apoptosis of cancer cells can be directly caused; and includes an immunotherapy agent as an active ingredient so that tumor size can be effectively suppressed even with the passage of time. Therefore, as a material that enables complex treatment combined with photothermal therapy and immunotherapy, the temperature-sensitive hydrogel of the present invention having the aforementioned effect can be usefully utilized in the field of medicine for cancer treatment.
Resumen de: US2025177558A1
Compositions, methods, and kits are provided for treating bacterial infections with nanoclusters comprising a metallic core conjugated to a nucleotide. Recalcitrant infections are often difficult to treat because of the presence of persister cells, a subpopulation of bacterial cells that is highly tolerant of traditional antibiotics. Persister cells are dormant, which makes them less susceptible to many antibiotics, which are designed to kill growing cells. Administration of nanoclusters comprising a nucleotide was found to be highly efficacious in eradicating persister cells and for treating infections for a broad range of bacterial species, including Gram-positive and Gram-negative bacteria. Such treatment was effective not only in eradicating planktonic bacteria but also bacteria in biofilms.
Resumen de: US2025179015A1
The present invention provides an ionizable lipid compound having an optimized carbon chain length and an amine head so that the ionizable lipid compound has increased delivery efficiency for an active molecule including, but not limited to, nucleic acids, proteins, small molecule drugs and the like. The present invention further relates to a lipid nanoparticle (LNP) comprising the ionizable lipid compound and the active molecule, and a pharmaceutical composition comprising the lipid nanoparticle.
Resumen de: US2025179034A1
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
Resumen de: US2025177479A1
An embodiment relates to a depsipeptide-based building block for inhibiting protein-protein interactions, a nanostructure including the same, and a use thereof, wherein the depsipeptide-based building block may remain in the body and cells for a long time when administered in vivo and be delivered to a target tissue with high efficiency, and a peptide for inhibiting protein-protein interactions may be gradually released over a long time to obtain a high effect.
Resumen de: US2025177461A1
A particle containing a virus encapsulated in an amorphous silica shell is described, wherein the amorphous silica shell is directly deposited about the surface of the virus. Also described is a method of producing a virus encapsulated in an amorphous silica shell, the method comprising enriching or purifying a virus; suspending the virus in buffer, hydrolysing a silica precursor directly contacting the hydrolysed silica precursor with the surface of the virus in buffer and encapsulating the virus in an amorphous silica shell.
Resumen de: US2025177305A1
A method of producing a lipid-encapsulated RNA nanoparticle, comprising the steps a) flowing an aqueous solution comprising an RNA through a 1st tube having an inner diameter (ID) of between about 0.1″ and 0.132″; b) flowing an ethanol solution comprising lipids through a 2nd tube having an ID of between about 0.005″ and 0.02″ at one third the flow rate of the aqueous solution through the 1st tube, wherein the lipids comprise a cationic lipid; and c) mixing the ethanol solution with the aqueous solution by flowing the ethanol solution and the aqueous solution into a mixing module consisting of the 2nd tube perpendicularly joined to the 1st tube; wherein the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about 10% to 75% ethanol v/v, and wherein the lipid-encapsulated RNA nanoparticles have a bilayer structure.
Resumen de: JP2023120371A
To provide a composition including an improved lipid-based nanoparticle, achieving reduction in the delivery of API to an in vivo undesirable tissue and also reduction in toxicity.SOLUTION: A composition comprises a lipid-based nanoparticle, wherein the nanoparticle is enclosed by a bipolar lipid membrane, which comprises cholesterol, dicetyl phosphate, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and (biotin DHPE), wherein the membrane further comprises at least one agent selected from the group consisting of stearoyl lysophosphatidylcholine and m-cresol, wherein the membrane comprises cholesterol, dicetyl phosphate, DSPC, stearoyl lysophosphatidylcholine, m-cresol, and biotin DHPE in a certain ratio such as 9.4:18.1:56.8:14.1:0.0:1.5, wherein the biotin-DHPE extends outward from the nanoparticle, and wherein the size of the nanoparticle ranges from about 10 nm to about 150 nm.SELECTED DRAWING: None
Resumen de: US2025177576A1
The present invention relates to new compounds and uses of these compounds for determining oxygen levels in a sample medium.The compounds of the invention are compounds according to Formula (I):wherein,M is a transition metal;R1, R2, R3, R4, R5, R6, R7 and R8 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C14 aryl, optionally substituted heteroaryl and —N(Y)2;n is 0 to 4;Y is a C1-C6 alkyl, or a C1-C6 haloalkyl;X is C or N; andZ is independently selected from the list consisting of S, Se, and Te.
Resumen de: US2025177577A1
The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.
Resumen de: US2025177561A1
The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.
Resumen de: US2025177562A1
Provided are aerosolized pharmaceutical compositions including comprising aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs). Also provided herein are methods of administering the aerosolized pharmaceutical compositions described herein.
Resumen de: US2025177559A1
There are provided herein, inter alia, complexes, compositions and methods for the delivery of nucleic acid into a cell in vivo. The complexes, compositions and methods may facilitate complexation, protection, delivery and release of oligonucleotides and polyanionic cargos into target cells, tissues, and organs both in vitro and in vivo.
Resumen de: US2025177318A1
Provided are functional segregated telodendrimers having, for example, two or three functional segments. The telodendrimers can aggregate to form nanocarriers. The telodendrimers can have one or more tetracycline drugs (such as CMT-3) physically bound thereto that release under physiological conditions. Such nanocarriers with loaded CMT-3 disperse stably in aqueous solution and may be used in treating inflammatory disease through local or systemic administration. Also provided are methods of treating acute respiratory distress syndrome (ARDS) and/or CARDS in a subject in need thereof, including: administering a therapeutically effective amount of CMT-3 and one or more nonantimicrobial host-modulators directly to the lungs of the patient. In embodiments, CMT-3 is administered to the lungs in an aerosolized formulation. In embodiments, subsequent to CMT-3 administration, one or more non-antimicrobial host-modulators directly to the lungs of the patient.
Resumen de: US2025170198A1
The present invention provides a lotus-derived extracellular vesicle (LDEV), which are extracted from lotus leaves by a group selected from the following extraction methods: polymer precipitation method, ultracentrifugation method, ultrafiltration method, density gradient centrifugation method and size-exclusion chromatography. The present invention also provides an anti-inflammatory composition containing the LDEV and the use of the LDEV. The LDEV extracted through different separation methods in the present invention have similar particle sizes and stable zeta potentials. In addition, the present invention has experimentally confirmed that the LDEV can be used to alleviate inflammatory reactions or wound healing, and can further be prepare as anti-inflammatory or wound healing drugs, compositions or nutritional supplements.
Resumen de: WO2024026444A1
Non-invasive, in situ forming depots for delivery of a therapeutic agents, containing heterodimerizing, synthetic leucine zippers for physical crosslinking mediated by competition-based dimerization. The heterodimerizing, synthetic leucine zippers form a self-assembling depot of the therapeutic agent at a target site in vivo. A library of such heterodimerizing, synthetic leucine zippers is provided, as well as methods of treating subjects using the same.
Resumen de: WO2024026029A2
Disclosed are compositions and methods related to lipid nanoparticles (LNPs) comprising ionizable lipids. The LNPs can comprise nucleic acid sequences encoding therapeutic peptides for immunotherapy, for example, bispecific antibodies or antigen binding fragments thereof.
Resumen de: EP4563142A1
The present invention relates to lipid nanoparticles capable of delivering a target substance to hepatic stellate cells. The lipid nanoparticles are for delivering a target substance to hepatic stellate cells and comprise a pH-sensitive cationic lipid including a hydrophilic portion and two hydrophobic portions, wherein an acid dissociation constant pKa of a lipid membrane constituting the lipid nanoparticles is greater than or equal to 6.7 and less than 8.2.
Nº publicación: EP4563528A1 04/06/2025
Solicitante:
SERVICIO ANDALUZ DE SALUD [ES]
UNIV MALAGA [ES]
Servicio Andaluz de Salud,
Universidad De Malaga
Resumen de: EP4563528A1
The present invention relates to a silica mesoporous nanoparticle comprising a covalently bound protein G' or protein A, the composition comprising said nanoparticle, the use thereof for capturing, purifying, eliminating and/or isolating immunoglobulins, preferably IgG, as well as a method for purifying an immunoglobulin, methods for pre-treating samples in order to subsequently diagnose allergies, infections and/or autoimmune diseases in a patient, and said diagnostic methods.
BOPI
Sede Electrónica
